A. Gemici, Hüseyin Saffet Beköz, Ö. G. Sevindik, Sevil Sadri, İstemi Serin, Vedat Buğra Erol, F. Sargın, Leylagül Kaynar
{"title":"Otolog Kök Hücre Transplantasyonunda Sitomegalovirüs (CMV) ve Hepatit B (HBV) Reaktivasyonu: Tek Merkez Deneyimi","authors":"A. Gemici, Hüseyin Saffet Beköz, Ö. G. Sevindik, Sevil Sadri, İstemi Serin, Vedat Buğra Erol, F. Sargın, Leylagül Kaynar","doi":"10.5578/llm.20229802","DOIUrl":null,"url":null,"abstract":"Objective: Cytomegalovirus (CMV) reactivation is a frequently encountered clinical condition during allogeneic hematopoietic stem cell transplantation. Hepatitis B reactivation (HBV) can occur asymptomatically only with re-emergence or increase in blood HBV-DNA levels, as well as in different clinical manifestations, including acute hepatitis and fulminant liver failure. While allogeneic hematopoietic stem cell transplantation is an independent risk factor, the risk for autologous hematopoietic stem cell (HSC) recipients and its effects on the transplantation statistically significantly higher than the patient group without CMV reactivation. Conclusion: Autologous stem cell transplantation also constitutes an important type of treatment to be careful in terms of viral reactivation.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"31 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"LLM Dergi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5578/llm.20229802","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Cytomegalovirus (CMV) reactivation is a frequently encountered clinical condition during allogeneic hematopoietic stem cell transplantation. Hepatitis B reactivation (HBV) can occur asymptomatically only with re-emergence or increase in blood HBV-DNA levels, as well as in different clinical manifestations, including acute hepatitis and fulminant liver failure. While allogeneic hematopoietic stem cell transplantation is an independent risk factor, the risk for autologous hematopoietic stem cell (HSC) recipients and its effects on the transplantation statistically significantly higher than the patient group without CMV reactivation. Conclusion: Autologous stem cell transplantation also constitutes an important type of treatment to be careful in terms of viral reactivation.